The 2018 CAP/AMP/IASLC (College of American Pathologists/Association of Molecular Pathology/International Association for the Study of Lung Cancer) guidelines (3) advocated testing for EGFR, ALK, ROS1, and BRAF upfront. The gene discussed is EGFR; the disease is lung carcinoma.